International acclaim for new breast cancer treatment

In In The News by Barbara Jacoby


India-based healthtech company Niramai has received international acclaim at the recent San Antonio Breast Cancer Symposium (SABCS). It was the only Indian company to present at one of the largest breast cancer conferences in the world, which is well-attended by oncologists and cancer researchers.

Niramai had the opportunity to speak about its work at the event, with Dr Geetha Manjunath, CEO and CTO, explaining that its solution uses AI to detect early stage breast cancer with results comparable to standard modalities. The solution, Thermalytix, is an automated diagnostic tool that combines thermal imaging with AI. It is radiation-free, accurate, automated and works on all women irrespective of their breast density.

“We were privileged to get an opportunity to present at SABCS 2018, a prestigious forum for interaction and learning for a broad spectrum of medical practitioners, researchers and health professionals with a special interest in breast cancer,” said Dr Geetha Manjunath.

At the conference, Niramai presented results of a retrospective multisite comparative study of 247 patients across three reputed cancer hospitals in India. These demonstrated higher sensitivity and comparable specificity of the solution to mammography.

US-based radiologists were receptive towards the solution, with, for example, Dr Sheldon Feldman, a New York-based expert in breast surgery and surgical oncology, saying: “I am very intrigued by this promising technology. It looks like a major advance in technology. I hope to collaborate and be helpful to further validate its efficacy”.